Group 1 - The core viewpoint of the report indicates that while the order situation for Tigermed (3347.HK) has improved, the market is more focused on the company's order conversion revenue efficiency and investment realization capability [1] - Citic Securities has lowered Tigermed's earnings forecast for the fiscal year 2027 by 7% to reflect increased uncertainty regarding long-term investment returns [1] - The target price for Tigermed's H-shares has been reduced from HKD 68.2 to HKD 59.9, and the target price for its A-shares has been decreased from RMB 81.9 to RMB 72 [1]